[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Voso MT, Hohaus S, Guidi F, Fabiani E, D'Alò F, Groner S, Späth D, Doehner K, Leone G, Doehner H, Schlenk RF: Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia; 2008 Sep;22(9):1685-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia.
  • Glutathione S-transferases (GSTs) are phase II detoxification enzymes involved in the metabolism of carcinogens and anticancer drugs, known also to interact with kinase complexes during oxidative or chemical stress-induced apoptosis.
  • We were interested whether their polymorphic variants may account for differences in outcome of patients with acute myeloid leukemia (AML) following chemotherapy.
  • We studied the prognostic role of polymorphisms in three GST genes (GSTP1/M1/T1) in a large patient cohort of the German Austrian Acute Myeloid Leukemia Study Group, treated according to prospective multicenter clinical trials (AML HD98A: 254 patients; AML HD98-B: 100 patients), with a median follow-up of 46 months.
  • Looking at short-term adverse drug reactions, homozygous carriers of the GSTP1*105 Val allele had a faster neutrophil and platelet recovery (P=0.002 and 0.02, respectively) and a reduced need of red cell and platelet transfusions (P=0.01 and 0.03, respectively).
  • Response to induction chemotherapy did not vary according to GST polymorphisms.
  • [MeSH-major] Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Blood Platelets / cytology. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neutrophils / cytology. Prognosis. Remission Induction. Survival Analysis


2. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia; 2009 Apr;23(4):641-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
  • Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells.
  • Conversely, AML blasts from patients treated with chemotherapy not including ATRA or VPA did not show any induction of NKG2D-L transcription.
  • Furthermore, upon therapy with ATRA or VPA, leukaemic blasts become able to trigger lytic granule exocytosis by autologous CD8(+) T and natural killer lymphocytes, as shown by CD107a mobilization assay, followed by leukaemic cell lysis.
  • [MeSH-major] Intercellular Signaling Peptides and Proteins / genetics. Leukemia, Myeloid, Acute / drug therapy. NK Cell Lectin-Like Receptor Subfamily K / metabolism. Transcriptional Activation / drug effects. Tretinoin / administration & dosage. Valproic Acid / administration & dosage
  • [MeSH-minor] Adult. Aged. Blast Crisis / drug therapy. Blast Crisis / pathology. Cytotoxicity, Immunologic / drug effects. Female. GPI-Linked Proteins. Histone Deacetylase Inhibitors. Humans. Ligands. Lymphocyte Activation / drug effects. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151770.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / ULBP2 protein, human; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


3. Reisch N, Roehnisch T, Sadeghi M, Greiner L, Regenbogen C, Rieger J, Emmerich B, Oduncu F: AML M1 presenting with recurrent acute large arterial vessel thromboembolism. Leuk Res; 2007 Jun;31(6):869-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML M1 presenting with recurrent acute large arterial vessel thromboembolism.
  • Acute leukemia may be associated with coagulopathy, predominantly severe bleeding diathesis caused by disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis.
  • Disordered hemostasis is characteristic for acute promyelocytic leukemia (APL, FAB M3).
  • We report a case of severe recurrent acute arterial thromboembolism at presentation in AML FAB M1.
  • Most likely, the ischemic events in our patient resulted from leukemia as the thrombus material included many leukemic blasts.
  • Despite leg amputation just a couple of hours before and extremely high infectious risk of the patient, chemotherapy was administered.
  • The clinical course of cessation of the ischemic events and a fast reduction of the blasts in the peripheral blood smear after chemotherapeutic treatment of the patient outlines the importance and life saving role of early chemotherapy even under adverse circumstances.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Thromboembolism / etiology
  • [MeSH-minor] Adult. Amputation. Disseminated Intravascular Coagulation / etiology. Female. Hemorrhagic Disorders / etiology. Humans. Iliac Artery / pathology. Iliac Artery / radiography. Ischemia / etiology. Ischemia / pathology. Ischemia / radiography. Ischemia / surgery. Leg / blood supply. Leg / pathology. Leg / radiography. Leg / surgery. Leukemia, Promyelocytic, Acute / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011031.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Voso MT, D'Alo' F, Putzulu R, Mele L, Scardocci A, Chiusolo P, Latagliata R, Lo-Coco F, Rutella S, Pagano L, Hohaus S, Leone G: Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood; 2002 Oct 15;100(8):2703-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia.
  • Glutathione S-transferases (GSTs) are enzymes involved in the detoxification of several environmental mutagens, carcinogens, and anticancer drugs.
  • GST polymorphisms resulting in decreased enzymatic activity have been associated with several types of solid tumors.
  • We determined the prognostic significance of the deletion of 2 GST subfamilies genes, M1 and T1, in patients with acute myeloid leukemia (AML).
  • The relevance of GSTM1 and GSTT1 homozygous deletions was studied with respect to patient characteristics, response to therapy, and survival.
  • GST deletions predicted poor response to chemotherapy (P =.04) and shorter survival (P =.04).
  • The presence of at least one GST deletion proved to be an independent prognostic risk factor for response to induction treatment and overall survival in a multivariate analysis including age and karyotype (P =.02).
  • In conclusion, individuals with GSTM1 or GSTT1 deletions (or deletions of both) may have an enhanced resistance to chemotherapy and a shorter survival.
  • [MeSH-major] Gene Deletion. Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / genetics. Sequence Deletion
  • [MeSH-minor] Aged. Base Sequence. DNA Primers. Female. Genotype. Humans. Karyotyping. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome


5. Suzuki A, Kimura Y, Ohyashiki K, Kitano K, Kageyama S, Kasai M, Miyawaki S, Ohno R: Trisomy 10 in acute myeloid leukemia. Three additional cases from the database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95. Cancer Genet Cytogenet; 2000 Jul 15;120(2):141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 10 in acute myeloid leukemia. Three additional cases from the database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95.
  • To clarify the clinical and hematologic features of a rare numerical chromosome abnormality, we searched for trisomy 10 in acute myelogenous leukemias (AMLs) using the database of the Japan Adult Leukemia Study Group (JALSG) AML 92 and 95.
  • The first patient had an AML-M1 morphology with CD7 antigen; the patient obtained complete remission (CR) with the first course of chemotherapy.
  • The second patient had an AML-M1 morphology without expressing CD7 antigen; this patient obtained CR, but relapsed 3 months later, and underwent allogeneic bone marrow transplantation.
  • In the literature, the mean age of patients with trisomy 10 AML is 57.8 years, the gender ratio is M/F = 1.5, and the frequency of M0/M1/M2 is 85.7%.
  • 8%) of CD7 expression of leukemia cells is notable.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Leukemia, Myeloid, Acute / genetics. Trisomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD7 / analysis. Databases as Topic / statistics & numerical data. Fatal Outcome. Female. Humans. Japan / epidemiology. Karyotyping. Male. Middle Aged


6. Suzuki A, Ohyashiki K, Kimura Y, Yamada H, Sano F, Miyawaki S, Kuriyama K, Ohno R, Japan Adult Leukemia Study Group: Trisomy 11 acute myeloid leukemia: 5 additional cases from the Japan Adult Leukemia Study Group AML-92 and AML-95 databases. Int J Hematol; 2000 Dec;72(4):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 11 acute myeloid leukemia: 5 additional cases from the Japan Adult Leukemia Study Group AML-92 and AML-95 databases.
  • We searched for trisomy 11 in acute myelogenous leukemia (AML) patients using the Japan Adult Leukemia Study Group (JALSG) AML-92 and -95 databases to clarify the clinical and hematologic features of a rare numerical chromosome abnormality.
  • The patients were 4 women and 1 man with trisomy 11 AML, all aged more than 45 years (median, 52 years), with 4 M1 morphologies and 1 M2.
  • No patients manifested hepatosplenomegaly or lymph node enlargement, and no central nervous system leukemia or extramedullary lesions were detectable.
  • Except for 1 patient, all achieved complete remission after 1 course of induction chemotherapy, but 2 relapsed after discontinuation of chemotherapy.
  • A third case of relapse occurred during intensification of chemotherapy, and the patient underwent allogenic bone marrow transplantation but died from interstitial pneumonia.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid / genetics. Trisomy / pathology
  • [MeSH-minor] Acute Disease. Aged. Databases, Factual. Female. Humans. Immunophenotyping. Japan. Male. Middle Aged


7. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, Baruchel A, FRALLE group: Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer; 2009;9:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
  • BACKGROUND: We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children.
  • After conventional four-drug induction, children were stratified by availability of an HLA-matched sibling.
  • Thirty-one children were good responders to prednisone, defined on day 8, and 21 were good responders to chemotherapy, defined by day-21 bone marrow (M1).
  • Based on multivariate analysis, two groups showed marked differences in five-year outcome: children with age<10, leukocyte count <100,000/mm3 and day-21 M1 marrow had a more favorable prognosis (14 pts: 100% CR, event free survival [EFS]: 57%, overall survival [OS]: 79%), than the high-risk group (22 patients: 55% CR, EFS: 18%, OS: 27%) (p < 0.005).
  • CONCLUSION: Age, leukocyte count and early response to treatment defined by the D21 bone marrow response provide an accurate model for outcome prediction.
  • The combination of available tools such as minimal residual disease assessment with determination of these simple factors could be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / drug effects. Leukocyte Count. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Anthracyclines. Asparaginase. Benzamides. Bone Marrow Transplantation. Child. Child, Preschool. Cortisone. Female. Humans. Imatinib Mesylate. Infant. Male. Prednisone / administration & dosage. Recurrence. Treatment Outcome. Vincristine. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1341-9 [17312329.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1723-4 [18056006.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1700-6 [12970767.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):39-45 [14566329.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1292-5 [7632935.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1493-6 [9305603.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • (PMID = 19144139.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 8A1O1M485B / Imatinib Mesylate; EC 3.5.1.1 / Asparaginase; V27W9254FZ / Cortisone; VB0R961HZT / Prednisone; FRALLE 93 protocol
  • [Other-IDs] NLM/ PMC2629767
  • [Investigator] Pautard B; Bauduer JF; Abgrall JF; Berthou C; Paillard C; Kanold J; Couillault G; Damay M; de Lumley L; Michel G; Thuret I; Chambost H; Bordigoni P; Sommel D; Leblanc T; Schaison G; Tabone MD; Donadieu J; Landman-Parker J; Auvrignon A; Thomas C; Fisher A; Dommergues JP; Bader-Meunier B; Bernaudin F; Lemerle S; Choulot J; Doireau V; Edan C; Bergeron C; Schneider P; Lamagnere JP; Berger C; Cornu G; Vermylen C
  •  go-up   go-down


8. Johansson B, Axelsson P, Billström R, Strömbeck B, Arheden K, Olofsson T, Cervin A, Adriansson M, Tanke HJ, Mitelman F, Fioretos T: Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity? Genes Chromosomes Cancer; 2001 Mar;30(3):261-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
  • Three adult de novo acute myeloid leukemias (AML M1, M2, and M4) with an isochromosome 7p are presented.
  • Although the patients were elderly--68, 72, and 78 years old--they all responded very well to chemotherapy, achieving complete remission lasting more than a year.
  • Furthermore, the breakpoints also differed within one of the cases, being located on both the proximal and the distal side of the most centromeric probe used.
  • Based on our three patients, as well as on a previously reported 82-year-old patient with AML M2 and idic(7)(q11) as the only chromosomal change, we suggest that this abnormality, as the sole anomaly, is associated with AML in elderly patients who display a good response to induction chemotherapy and, hence, have a favorable prognosis.
  • [MeSH-major] Aging / genetics. Chromosomes, Human, Pair 7 / genetics. Isochromosomes / genetics. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Banding. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. In Situ Hybridization, Fluorescence / methods. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Male. Remission Induction. Thioguanine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11170283.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; FTK8U1GZNX / Thioguanine; ZRP63D75JW / Idarubicin; LAI regimen
  •  go-up   go-down


9. Lu Y, Jin J, Chen ZM, Lou JY, Xu WL: [Analysis of 32 cases of acute leukemia with abnormality of chromosome 7]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec;21(6):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 32 cases of acute leukemia with abnormality of chromosome 7].
  • OBJECTIVE: To explore the incidence and prognostic significance of chromosome 7 anomaly in acute leukemia.
  • METHODS: Conventional cytogenetic analysis of R-band was used to detect the abnormalities of chromosome 7 in 410 acute leukemia patients.
  • The incidence of -7/7q- in M0, M1 and M2 was higher than that in other subtypes of acute myeloid leukemia (AML).
  • In 30 cases treated with chemotherapy, 11 cases acquired complete remission (CR) and the CR rate was lower than that for all concurrent cases of acute leukemia(36.7% vs 65.8%); the CR rate of AML with -7/7q- was lower than that of AML with normal karyotype(25% vs 55.6%).
  • There was no difference in the CR rate between acute lymphocytic leukemia(ALL) with -7/7q- and ALL with normal chromosome (57.1% vs 77.8%), but 4 cases with -7/7q- which attained complete remission for a time relapsed early.
  • CONCLUSION: -7/7q- was the frequent aberration in chromosome 7 anomaly, which was often detected in M0, M1 and M2.
  • It might be associated with the pathogenesis of acute leukemia; the patients with chromosome 7 anomaly had poorer prognosis.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 7. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583990.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Aoyama Y, Yamane T, Kanashima H, Takeoka Y, Koh K, Nakao Y, Yamamura R, Nakamae H, Ohta K, Inoue T, Hino M, Tatsumi N: [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence]. Rinsho Ketsueki; 2001 Apr;42(4):314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
  • A 42-year-old man was diagnosed as having acute myelocytic leukemia in July 1998.
  • The leukemic cells tended to be differentiated, and on the basis of positive peroxidase staining, this case was considered to be AML (M2) according to the FAB classification. t(8;21)(q22;q22) chromosomal abnormality was observed, but surface antigen analysis revealed no expression of either CD13 or CD33, a finding characteristic of myelocytic leukemia.
  • Combination chemotherapy resulted in complete remission, and allogeneic bone marrow transplantation was performed with donor cells from the patient's sister.
  • Unfortunately, however, the patient died about 18 months after the onset of leukemia.
  • Comparison of the findings at recurrence with those at initial diagnosis revealed morphological changes in non-differentiated immature cells (AML-M1) and CD13 surface antigen expression.
  • [MeSH-major] Antigens, CD / immunology. Antigens, CD13 / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Flow Cytometry. Humans. Male. Phenotype. Recurrence. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11400303.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


11. Ullah K, Ahmed P, Raza S, Satti TM, Chaudhry QU, Akhtar F, Kamal MK, Akhtar FM, Khan B: Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi. J Pak Med Assoc; 2007 Sep;57(9):434-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
  • OBJECTIVE: To evaluate the outcome in denovo AML patients treated with different remission induction and consolidation chemotherapy regimens in our population.
  • METHODS: A retrospective study on acute myeloid leukaemia (AML) patients was carried out at Armed Forces Bone Marrow Transplant Centre Rawalpindi Pakistan between July 2001 and June 2006.
  • During 5 years period 46 patients received treatment for AML at our centre.
  • These 46 patients were categorized into two groups on the basis of type of leukaemia and chemotherapy given.
  • In group-I 40 patients (group Ia: 23 patients of M1-M6, less M3 group Ib: 17 patients of AML M3) received anthracycline and cytarabin based chemotherapy.
  • In group-II, six patients (AML- M3) received all trans retinoic acid (ATRA) based chemotherapy.
  • RESULTS: In group Ia, out of 23 patients, 14 patients (60.8%) achieved complete remission (CR) after remission induction chemotherapy, 10 patients remained in CR after 3rd and 4th consolidation.
  • Eleven patients died and five patients relapsed during treatment and follow up.
  • Eleven patients died during treatment while one patient relapsed in this group.
  • In group II all patients achieved CR (100%) after 1st course of chemotherapy.
  • Two of these patients unfortunately died of uncontrolled sepsis during 1st consolidation, while remaining 4 patients 66.6% are on maintenance chemotherapy and are still in CR.
  • Survival in AML-M3 patients treated with ATRA based chemotherapy is significantly superior than anthracycline based chemotherapy (66.6% vs. 29.4%).
  • Infection and chemotherapy toxicity being major causes of mortality.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Cytarabine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Military Medicine. Military Personnel. Treatment Outcome. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Female. Humans. Male. Middle Aged. Pakistan. Retrospective Studies. Time Factors


12. Thiébaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E: Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol; 2000 Sep;79(9):501-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis.
  • Acute myeloid leukemia (AML) presenting with hyperleukocytosis is generally of poor prognosis due to an increased early death rate and a lower response to initial chemotherapy.
  • Morphologic subtypes, according to the French-American-British classification, showed 3 M0, 16 M1, 6 M2, 10 M4, 16 M5, and 2 unclassified cases of AML.
  • The median WBC count at the time of starting chemotherapy was 85 x 10(9)/l (range 23-264 x 10(9)/l).
  • In this study, early death rate is lower than data previously published in the literature and almost all patients could receive chemotherapy.
  • This might suggest a benefit of initial leukapheresis in the treatment of AML presenting with hyperleukocytosis.
  • [MeSH-major] Leukapheresis. Leukemia, Myeloid, Acute / therapy. Leukocytosis / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Treatment Outcome


13. Haase D, Binder C, Bünger J, Fonatsch C, Streubel B, Schnittger S, Griesinger F, Westphal G, Schoch C, Knopp A, Berkovicz D, Krieger O, Wörmann B, Hilgers R, Hallier E, Schulz T: Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res; 2002 Mar;26(3):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.
  • The most serious long-term complications of anti-tumor therapy are secondary malignancies.
  • Parameters which might allow an estimation of the individual risk to develop a therapy-induced neoplasia are urgently needed.
  • We examined whether the genotypes of the glutathione S-transferases (GST) M1 and T1, which metabolize various cytostatic drugs, as well as reactive oxygen species, influence the risk for secondary neoplasia.
  • In a retrospective study, we analyzed peripheral blood lymphocyte or bone marrow DNA samples from 213 patients with acute myeloid leukemia (AML) and 128 with myelodysplastic syndromes (MDS) 44 of whom suffered from therapy-associated AML/MDS.
  • We conclude that patients with carcinoma of the breast and inheritance of a combined gene deletion of GSTM1 and GSTT1 might bear an increased risk to develop a secondary therapy-induced hematologic neoplasia.
  • An insufficient detoxification of cytostatic drugs such as cyclophosphamide is suggested to represent the underlying pathomechanism.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / enzymology. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / genetics. Breast Neoplasms, Male / radiotherapy. Chromosome Aberrations. Female. Genotype. Homozygote. Humans. Karyotyping. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Leukemia, Radiation-Induced / etiology. Lymphocytes / enzymology. Male. Middle Aged. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / genetics. Radiotherapy / adverse effects. Retrospective Studies. Risk Factors. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792413.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


14. Okoshi Y, Shimizu S, Kojima H, Obara N, Mukai HY, Komeno T, Hasegawa Y, Mori N, Nagasawa T: Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation. Acta Haematol; 2001;105(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation.
  • A 29-year-old woman having acute myelogeneous leukemia-M1 subtype with the chromosomal abnormality t(16;21)(p11;q22) is presented.
  • Complete blood count at onset showed a hemoglobin level of 7.2 g/dl, a platelet count of 48 x 10(9)/l, and a white blood cell count of 161.2 x 10(9)/l with 99% blasts and 1% lymphocytes.
  • After achieving complete remission following conventional chemotherapy, she received an HLA-matched bone marrow transplantation (BMT) from her sibling after conditioning with busulfan, etoposide and cyclophosphamide.
  • However, 9 months later, the leukemia relapsed as a painful extramedullary mass in her left femur.
  • In spite of intensive re-induction chemotherapy, she died of progressive disease and sepsis.
  • We consider that even high-dose chemotherapy with BMT may not be effective in the eradication of this type of leukemia, and that the detection of minimal residual disease possibly contributes to the better planning of the therapeutic strategy.
  • [MeSH-major] Bone Marrow Transplantation. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Leukemia, Myeloid, Acute / genetics. Neoplasm, Residual / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD13 / analysis. Antigens, CD34 / analysis. Antigens, CD56 / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Fatal Outcome. Female. Hemoglobins / analysis. Humans. Karyotyping. Leukocyte Count. Peroxidase / analysis. Platelet Count. Radiotherapy. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Sialic Acid Binding Ig-like Lectin 3. Transplantation, Homologous. Treatment Failure

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11340253.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, CD56; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Hemoglobins; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 1.11.1.7 / Peroxidase; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


15. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H: Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol; 2004 Feb;72(2):89-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
  • There is evidence to suggest, that those receptors (R) could play a role in leukemia with respect to cell differentiations and its regulation, prognosis, and pathobiology.
  • Knowledge of individual cytokine receptor (CKR) profiles could provide new discoveries about CKR-supported therapeutic considerations.
  • METHODS: We have studied the expression of CKR on mononuclear bone marrow (BM) cells of 89 patients with acute myeloid leukemia (AML) at first diagnosis, three patients at relapse or with persisting AML and eight healthy probands by fluorescence-activated cell sorting (FACS) analysis using directly fluorescein-conjugated antibodies: CD114 (hG-CSF-R), CD116 (hGM-CSF-R), CD117 (hSCF-R), CD123 (hIL-3-R), CD130 (gp130subunit), CD135 (hFL-R).
  • Within the French-American-British (FAB) types we observed a maturation- and lineage (granulocytic/monocytic)-committed expression profile.
  • Monocytic subtypes (FAB-type M4/M5) showed significantly more GM-CSF-R(+) (P = 0.001) and FL-R(+) (P = 0.001) and significantly less stem cell factor-R (SCF-R(+)) (P = 0.02) cases.
  • Highest proportions of G-CSF-R(+) blasts were observed in FAB-type M3.
  • In undifferentiated leukemias (FAB-type M1, M2) high amounts of SCF-R(+), IL-3-R(+), and FL-R(+) blasts could be detected.
  • FL-R was the only CKR, which was positive in FAB-type M0 (n = 2).
  • CONCLUSION: We can conclude, that CKR-expression in AML is maturation- and lineage-committed and the proportions of especially early acting CKR have influence on relapse-free survival probability of AML-patients, independently of the karyotype.
  • With respect to the individual CKR status the benefit of cytokines as priming agents, as agents to treat neutropenia or to influence the metabolism of chemotherapy can be discussed under new points of view.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Receptors, Cytokine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recurrence. Time Factors


16. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, Zeng C, Baron A, Hunger SP, Varella-Garcia M, Gemmill R, Brizard F, Brizard A, Roche J: Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia; 2002 Feb;16(2):186-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.
  • We used a degenerate RT-PCR screen and subsequent real-time quantitative RT-PCR assays to examine the expression of HOX and TALE-family genes in 34 cases of chromosomally defined AML for which outcome data were available.
  • Higher levels of expression were also observed in the FAB subtype, AML-M1.
  • Thus, although HOX overexpression and clinical resistance to chemotherapy often coincide, they are not inextricably linked.
  • [MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Leukemic. Genes, Homeobox. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Chromosome Aberrations. Chromosomes, Human / genetics. Computer Systems. DNA Primers. Female. Follow-Up Studies. Gene Amplification. Homeodomain Proteins / biosynthesis. Humans. Male. Middle Aged. Multigene Family. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11840284.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


17. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, Hauswirth A, Schernthaner GH, Chott A, Natter S, Kraft D, Valenta R, Schwartz LB, Geissler K, Lechner K, Valent P: Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood; 2001 Oct 1;98(7):2200-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia.
  • Under physiologic conditions other myeloid cells are virtually tryptase negative.
  • However, tryptases are also expressed in several myeloid leukemia cell lines.
  • In this study, serum total tryptase levels were determined in 150 patients with acute leukemias (de novo acute myeloid leukemia [AML], n = 108; secondary AML, n = 25; acute lymphoid leukemia [ALL], n = 17) by fluoroenzyme immunoassay.
  • In de novo AML, elevated tryptase levels were frequently detected in patients with French-American-British classification M0 (6 of 9), M2 (9 of 14), M3 (4 of 6), and M4eo (7 of 7), and less frequently in M1 (7 of 20), M4 (6 of 26), M5 (2 of 18), M6 (0 of 5), or M7 (1 of 3).
  • In AML patients with elevated serum tryptase before chemotherapy, who entered complete remission, tryptase levels returned to normal or near normal values.
  • [MeSH-major] Leukemia, Myeloid / enzymology. Myeloid Cells / enzymology. Serine Endopeptidases / biosynthesis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Biomarkers. Bone Marrow Cells / enzymology. Bone Marrow Cells / pathology. Female. Humans. Immunohistochemistry. Male. Mast Cells / enzymology. Mast Cells / metabolism. Microscopy, Immunoelectron. Middle Aged. Monocytes / enzymology. Monocytes / metabolism. Monocytes / pathology. RNA, Messenger / analysis. Remission Induction. Tryptases

  • Genetic Alliance. consumer health - Leukemia, mast-cell.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568008.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI20487; United States / NIAMS NIH HHS / AR / AR45441
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / RNA, Messenger; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


18. Tóthová E, Stecová N, Kafková A, Fricová M, Guman T, Elbertová A: [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia]. Vnitr Lek; 2004 Feb;50(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia].
  • Flow cytometric expression of Bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-Bcl-2 monoclonal antibody by direct immunofluorescence technique and result were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The percentage of Bcl-2+ cells was higher in M0 and M1 types according French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel: control mean channel was significantly higher (p < 0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of Bcl-2 and MFI index of Bcl 2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15077589.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


19. Inuzuka M, Tokura Y: Sterile suppurative folliculitis associated with acute myeloblastic leukaemia. Br J Dermatol; 2002 May;146(5):904-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sterile suppurative folliculitis associated with acute myeloblastic leukaemia.
  • One month later, routine blood tests were abnormal, showing acute myeloblastic leukaemia (M1 in the French-American-British classification).
  • The follicular eruption improved promptly in response to chemotherapy for the leukaemia.
  • We suggest that this case may represent a rare, follicular variant of neutrophilic dermatosis associated with myelogenous leukaemia.
  • [MeSH-major] Folliculitis / etiology. Leukemia, Myeloid, Acute / complications. Sweet Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000394.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E: P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res; 2000 Aug;6(8):3205-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
  • Despite treatment with intensive chemotherapy, a considerable number of patients with acute myeloid leukemia (AML) die from their disease due to the occurrence of resistance.
  • Overexpression of the transporter proteins P-glycoprotein (P-gp) and multidrug resistance protein (MRP) 1 has been identified as a major cause of cross-resistance to functionally and structurally unrelated drugs.
  • A low Rh123 accumulation and a high Rh123 efflux blocking by PSC833 were associated with a low complete remission (CR) rate after the first cycle of chemotherapy (P = 0.008 and P = 0.01, respectively).
  • AML patients with French-American-British classification M1 or M2 showed a lower Rh123 accumulation than patients with French-American-British classification M4 or M5 (P = 0.02).
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporins / pharmacology. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Flow Cytometry. Fluoresceins / pharmacokinetics. Fluorescent Dyes / pharmacokinetics. Glutathione / metabolism. Humans. Male. Middle Aged. Multidrug Resistance-Associated Proteins. Propionates / pharmacology. Quinolines / pharmacology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Randomized Controlled Trials as Topic. Reverse Transcriptase Polymerase Chain Reaction. Rhodamine 123 / pharmacokinetics. Survival Analysis. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955805.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Cyclosporins; 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Propionates; 0 / Quinolines; 0 / RNA, Messenger; 1N3CZ14C5O / Rhodamine 123; 3301-79-9 / 6-carboxyfluorescein; 5Q9O54P0H7 / verlukast; GAN16C9B8O / Glutathione; Q7ZP55KF3X / valspodar
  •  go-up   go-down


21. Lee WL, Yuan CC, Chao HT, Chen PM, Lin HD, Wang PH: Vaginal obliteration after total body irradiation and chemotherapy as treatment for acute myeloid leukemia. Eur J Obstet Gynecol Reprod Biol; 2000 May;90(1):77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal obliteration after total body irradiation and chemotherapy as treatment for acute myeloid leukemia.
  • Although radiotherapy is an integral part in the management of certain types of hematological malignancies, its effect on the reproductive system has been well documented.
  • We report a rare complication where a patient had complete vaginal obliteration after receiving a dose of total body irradiation (1575 cGy) as part of her treatment for acute myeloid leukemia.
  • A 37-year-old married woman, G3P2, underwent high-dose cyclophosphamide accompanied by high dose (1575 cGy) total body irradiation (TBI) as part of her treatment for acute myeloid leukemia (AML: m1) when she was 35 years of age.
  • After TBI, the patient developed ovarian failure and amenorrhea, which was confirmed by hormonal evaluation.
  • Nevertheless, she did not receive any hormonal replacement therapy and stopped her sexual life for two years.
  • She initially received hormonal replacement therapy followed by surgical correction via vaginoplasty and two months of dilatory replacement and frequent coitus with satisfactory result.
  • In the present case report, it is unclear whether spontaneous vaginal obliteration resulted from chemotherapy, total body irradiation, or another unknown cause such as a concomitant leukemic infiltration of the vaginal wall, severe bacterial and fungal infection before treatment, or from any combination of the above.
  • However, due to this case presentation, we suggest that such patients must receive hormonal replacement therapy and be encouraged to have a normal sexual life to avoid this possible problem.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cyclophosphamide / adverse effects. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / radiotherapy. Vagina / pathology. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] Adult. Coitus. Combined Modality Therapy. Female. Hormone Replacement Therapy. Humans. Leukemic Infiltration. Sexual Abstinence

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767515.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


22. Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V: Long-term outcomes of de novo acute myeloid leukemia in Thai patients. J Med Assoc Thai; 2009 Sep;92(9):1143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
  • BACKGROUND: Acute myeloid leukemia (AML) is the heterogeneous disease.
  • Therefore, we conducted a retrospective study to analyze clinical outcomes and predictive factors of Thai AML patients receiving chemotherapy treatment.
  • Of 101 patients with non- M3 subtype, the patients received induction and consolidation chemotherapy with anthracyclin plus cytarabine based regimens (3 + 7).
  • All patients achieving complete remission (CR) were treated with intensive chemotherapy using intermediate dose cytarabine plus anthracyclin based protocol.
  • All patients with M3 subtype, the induction chemotherapy consisted of a combination of all-trans retinoic acid (ATRA) and anthracyclin.
  • All patients achieving complete remission (CR) were treated with three courses of mitoxantrone as consolidation chemotherapy, followed by maintenance chemotherapy with methotrexate, etoposide and ATRA.
  • Common subtypes were M4 (28.3%), M1 (26.4%) and M2 (20.8%).
  • Of the 96 evaluable patients, 60 (62.5%) achieved complete remission (CR), 38 (39.6%) with the first course of chemotherapy.
  • Median time to CR was 54 days (25-168 days).
  • Median follow-up time was 10.4 months, 5-year-DFS and 5-year-OS were 41 and 22.2%, respectively.
  • Poor-risk cytogenetic factors are associated with poor treatment outcomes.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Thailand. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772172.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH: cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. Int J Oncol; 2006 May;28(5):1065-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology and clinical course.
  • Until now the basis for prognostic evaluation and therapeutic decision has been the karyotype, genetic FLT3 abnormalities and the initial chemotherapy response.
  • Leave-one-out crossvalidation (LOOCV) showed with high accuracy that gene expression classifiers could predict if leukaemia samples belonged to the FAB AML-M1 or to the FAB AML-M2 groups.
  • Except for an accumulation of samples classified as FAB M1 and M2 in cluster 3, there was no evident relationship between the clusters and the FAB classification.
  • Each subgroup displayed clearly distinguished gene expression patterns validated using real-time quantitative PCR analysis.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged


24. Uzuka Y, Saito Y: [Cure of adult acute myeloblastic leukemia]. Nihon Rinsho; 2003 Nov;61(11):2035-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cure of adult acute myeloblastic leukemia].
  • Despite major recent advances in the understanding of the molecular biology of adult acute myeloblastic leukemia(AML), the treatment of the disease remains challenging.
  • This review summarizes literature in the field of curative chemotherapy for adult acute myeloblastic leukemia(AML).
  • In particular, detailed analysis of curing leukemia in patients treated with risk-oriented chemotherapy and in patients with APL was presented.
  • In addition, results using our curative chemotherapy approach for adult AML were reported.
  • Lastly, future directions for curing adult AML were discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Chromosome Aberrations. Clinical Trials as Topic. Humans. Prognosis. Risk. Tretinoin / administration & dosage

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619450.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  • [Number-of-references] 23
  •  go-up   go-down


25. Nishikawa M, Yamamoto M, Watanabe Y, Kita K, Shiku H: Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts. Int J Oncol; 2001 Mar;18(3):559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts.
  • We have previously shown that protein phosphatase-1 (PP1) is the most abundant Ser/Thr phosphatase in human adult primary leukemic cells.
  • To determine the clinical importance of PP1 expression, we compared PP1 activity of leukemic blasts with other putative prognostic factors in 46 patients with acute myelogenous leukemia (AML) who were treated with remission induction chemotherapy.
  • PP1 was ubiquitously but differently expressed in various FAB subtypes (M1-M5), although PP1 activity was significantly higher in blasts of AML-M4 than in AML-M2.
  • This preliminary study suggests that low PP1 activity may be associated with shortened survival time for AML patients with high white cell counts.
  • [MeSH-major] Leukemia, Myeloid, Acute / enzymology. Leukocytosis / enzymology. Phosphoprotein Phosphatases / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Antineoplastic Agents / therapeutic use. Cytosol / physiology. Female. Humans. Leukocyte Count. Male. Middle Aged. Prognosis. Protein Phosphatase 1. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11179487.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / Protein Phosphatase 1
  •  go-up   go-down


26. Zhang Y, Yang L, Li R, Zhang L, Zhang MR, Xiao ZJ: [The effects of glutathione S-transferase (GSTT1 and GSTM1) genes polymorphisms on treatment efficacy and prognosis of acute myeloid leukemia]. Zhonghua Nei Ke Za Zhi; 2006 Mar;45(3):213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effects of glutathione S-transferase (GSTT1 and GSTM1) genes polymorphisms on treatment efficacy and prognosis of acute myeloid leukemia].
  • OBJECTIVE: To investigate the impact of GSTT1 and GSTM1 genotypes on response, drug side effects and prognosis of acute myeloid leukemia (AML).
  • Complete remission (CR) rate, drug side-effects, overall survival, relapse-free survival and relapse rate were compared in groups with or without GSTT1 and GSTM1 genes. RESULTS:.
  • The risk of failure to achieve CR in patients with GSTT1 null/GSTM1 null is 8.736 times higher than that in patients with GSTT1 and GSTM1 genes double-present (odds ratio OR was 8.736, 95% CI was 1.146 - 66.574).
  • The CR rate (88.4%) in GSTT1 present patients was also significantly higher than that in patients of GSTT1 null (CR rate 74.7%) (P = 0.021, OR = 2.572, 95% CI 1.136 - 5.826). (2) There was no significant relationship between GSTT1/GSTM1 genotypes and the lasting time of neutrophilic granulocyte (ANC) < 0.5 x 10(9)/L and PLT < 20 x 10(9)/L.
  • The risk of ALT abnormality in patients with GSTM1 null is 2.593 times higher than that in patients with GSTM1 present (P = 0.016, 95% CI 1.176 - 5.717). (3) Overall survival and relapse-free survival of GSTT1 and GSTM1 double-present patients were significantly better than those in patients of GSTT1 null/GSTM1 null (mean overall survival was 68.4 months vs 38.5 months, P = 0.028, and mean relapse-free survival was 73.5 months vs 34.9 months, P = 0.014, respectively).
  • CONCLUSION: GSTT1 and GSTM1 genotypes were apparently related with response, drug side effects and prognosis of patients with AML.
  • GSTT1 and GSTM1 genotype might be useful in selecting appropriate chemotherapy regimens for patients with AML.
  • [MeSH-major] Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / drug therapy. Polymorphism, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624155.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


27. Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q, Nie K, Wu KF: Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res; 2004 Dec;28(12):1313-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P2X7 in human hematopoietic cell lines and leukemia patients.
  • Here, we investigated P2X7 expression in 11 human hematopoietic cell lines, representing different lineages, as well as bone marrow mononuclear cells (BMMC) samples from 87 leukemia and 10 myelodysplastic syndrome (MDS) patients.
  • Samples from 69 leukemia and 9 MDS patients were P2X7 positive at mRNA level.
  • Moreover, both positive rates and relative expression levels were significantly higher in acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and MDS groups than that in normal donor group.
  • The expression levels varied among AML subtypes with higher levels being observed in M4, M5, and M6 groups but not in M1 or M2 group.
  • Furthermore, after one course of standard induction therapies, the remission rate in high P2X7 expression group was lower than that in either P2X7 negative group or low P2X7 expression group.
  • [MeSH-major] Leukemia / genetics. Receptors, Purinergic P2 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Cells / chemistry. Bone Marrow Cells / chemistry. Calcium Signaling. Case-Control Studies. Cell Line. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology. RNA, Messenger / analysis. Receptors, Purinergic P2X7. Treatment Outcome. Tumor Cells, Cultured


28. Pagano L, Pulsoni A, Mele L, Tosti ME, Cerri R, Visani G, Melillo L, Candoni A, Clavio M, Nosari A, Petti MC, Martino B, Mele A, Levis A, Allione B, Almici C, Equitani F, Leone G, Mandelli F, Gruppo Italiano Malattie Ematologiche dell'Adults: Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. Ann Oncol; 2001 Feb;12(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group.
  • OBJECTIVE: To evaluate in a multicenter retrospective study, the clinical and laboratory characteristics and the outcome of patients with acute myeloid leukemia (sAML) previously diagnosed with breast cancer (BC) among an adult acute leukemia population.
  • PATIENTS AND METHODS: Between June 1992 and July 1996, 3934 new cases of adults with acute leukemia were recorded in GIMEMA Archive of Adult Acute Leukemia (2964 AML, 901 ALL, 69 acute leukemia expressing both myeloid and lymphoid surface markers).
  • Twenty-seven patients received chemo- and/or radiotherapy for breast cancer (7 only chemotherapy, 6 only radiotherapy, and 14 combined treatment).
  • All patients were surgically treated but in 10 patients surgical debridement was the sole therapy for breast cancer.
  • The drugs most frequently employed were alkylating agents (18 patients), topoisomerase II inhibitors (9 patients), antimetabolites (20 patients) (CMF, CEF and MMM combinations).
  • Considering morphological features, FAB subtypes were 4 M0, 5 M1, 11 M2, 5 M3, 8 M4, 3 M5, and 1 M6.
  • Thirty-four patients received chemotherapy for sAML, and twenty-five of them achieved a CR (74%), with a median duration of twenty-eight weeks (5-280+).

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300325.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Lee KW, Choi IS, Roh EY, Kim DY, Yun T, Lee DS, Yoon SS, Park S, Kim BK, Kim NK: Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience. Ann Hematol; 2004 Apr;83(4):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience.
  • Clinical features and treatment outcome of 31 patients over 16 years of age with t(8;21) acute myeloid leukemia (AML) were compared with 60 patients without t(8;21).
  • Among 31 patients with t(8;21), 15 patients were classified as AML-M2 and 11 and 5 patients as AML-M4 and M1, respectively.
  • Of these patients, 28 patients (90.3%) achieved complete remission and 22 patients received consolidative treatment: intermediate-dose cytarabine (IDAC) 11, high-dose cytarabine (HDAC) 6, and allogeneic bone marrow transplantation (BMT) 5.
  • When compared with patients without t(8;21), we could not demonstrate better treatment outcome for t(8;21) AML [median event-free survival (EFS) and overall survival (OS) 10.3 and 12.5 months in AML with t(8;21) vs 11.5 and 15.6 months in AML without t(8;21)].
  • In the t(8;21) AML group, patients who received HDAC consolidation did not show superior treatment outcome to those who received other consolidative treatment [median EFS: IDAC 11.9 months vs HDAC 9.2 months vs allogeneic BMT 38.1 months (P=NS) and median OS: IDAC 17.8 months vs HDAC 12.0 months vs allogeneic BMT 47.3 months (P=NS)].
  • Similar treatment outcome between patients with and without t(8;21) and non-superior treatment outcome of HDAC consolidative chemotherapy in the t(8;21) AML group in our study is contradictory to previous reports.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Myeloid / genetics. Leukemia, Myeloid / therapy. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Remission Induction. Treatment Outcome


30. Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, Fiere D, Thomas X: Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol; 2002 Oct;13(10):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of cigarette smoking on the presentation and course of acute myeloid leukemia.
  • BACKGROUND: It is known that cigarette smoking is associated with an approximately 50% increase in leukemia risk.
  • In order to detect a possible influence of cigarette smoking on initial characteristics at the time of presentation and on the course of the disease, we conducted a retrospective study in 643 patients with newly diagnosed acute myeloid leukemia.
  • Leukemia of French-American-British (FAB) M1 subtype was more frequent in non-smokers (P = 0.005).
  • However, a higher rate of severe pulmonary infection was observed in smokers during induction chemotherapy (P = 0.02).
  • Other characteristics associated with poor prognosis included mainly older age, unfavorable karyotype, secondary acute myeloid leukemia (AML) and elevated World Health Organization (WHO) performance status.


31. Tóthová E, Fricova M, Stecová N, Kafková A, Elbertová A: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma; 2002;49(3):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
  • Flow cytometric expression of bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The percentage of bcl-2+ cells was higher in M0 and M1 types according to French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel:control mean channel was significantly higher (p=0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of bcl-2 and MFI index of bcl-2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12097997.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


32. Matsuo K, Shimoya K, Ueda S, Wada K, Koyama M, Murata Y: Idarubicin administered during pregnancy: its effects on the fetus. Gynecol Obstet Invest; 2004;58(4):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute myeloblastic leukemia, subtype M1, was diagnosed in a 39-year-old G2P1 Japanese woman at 21 weeks' gestation.
  • Second-line chemotherapy, including idarubicin, performed for one cycle, was administrated during the early third trimester of pregnancy.
  • Complete remission was established with idarubicin including chemotherapy.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fetus / drug effects. Idarubicin / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Cesarean Section. Drug Therapy, Combination. Female. Gestational Age. Heart Rate, Fetal / drug effects. Humans. Placenta / drug effects. Placenta / pathology. Pregnancy. Shock, Septic / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15256824.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin
  •  go-up   go-down


33. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP: Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia; 2005 Oct;19(10):1812-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant.
  • Human myeloid leukemia cell lines are induced to terminal differentiation into monocyte lineage by 1,25-dihydroxyvitamin D3 (1,25D3) or its analogs (deltanoids).
  • Our studies suggest that patients with CML or AML subtypes M2 and M4, but not M1, M3 or M4eo, are particularly suitable for this combination therapy.
  • We conclude that the established cell line HL60 presents a good model for some, but not all, subtypes of myeloid leukemia, and that the JNK pathway plays an important role in monocytic differentiation of human leukemic cells ex vivo, as well as in vitro.
  • [MeSH-major] Antioxidants / therapeutic use. Cell Differentiation / drug effects. Enzyme Inhibitors / therapeutic use. Leukemia, Myeloid / drug therapy. Vitamin D / analogs & derivatives. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Calcium / metabolism. Cell Lineage. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Monocytes / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107889.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Enzyme Inhibitors; 1406-16-2 / Vitamin D; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


34. Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M: [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes]. Vnitr Lek; 2003 Mar;49(3):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
  • Between February 1991 and April 1994 induction chemotherapy of 32 adult consecutive patients under 65 years with de novo acute myeloid leukemias (AML) was started in the study UHKT-911.
  • Their AML were classified according to the FAB classification: 3 M0, 3 M1, 9 M2, 14 M4, 3 M5.
  • Induction chemotherapy consisted of 1-2 cycles with 3-4 doses of daunorubicin (DNR) 45 mg/m2/d i.v. and 14 doses of cytosine arabinoside (Ara-C) 200 mg/m2 per 3-h infusion every 12 hours.
  • After the treatment patients, not being in complete remission, got the HD cycle with 10 high-doses of Ara-C 2000 mg/m2 per 3-h infusion every 12 hours i.v. and DNR 45 mg/m2/d i.v. on days 4 and 5, then the EMi cycle composed of etoposide 100 mg/m2/d i.v. for 5 days and mitozantrone 10-12 mg/m2/d i.v. on days 1, 3 and 5.
  • Five patients died between days 5 and 24 of treatment of infections, two patients were resistant to 4 cycles of induction therapy and survived 8.4 and 13.5 months.
  • After 62 months in CR a pancytopenia with dysplastic bone marrow changes developed in one of them, probably a secondary myelodysplastic syndrome, lasting for further 33 months.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12728590.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


35. Vehreschild JJ, Krüger K, Kurzai O, Wickenhauser C, Behringer K, Töx U, Cornely OA: Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses; 2006;49 Suppl 1:42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation.
  • We report on the treatment course of a 27-year-old male patient with acute myeloid leukaemia M1 and chronic disseminated candidiasis.
  • After induction chemotherapy, the patient developed oesophageal candidiasis while participating in a voriconazole vs. placebo prophylaxis trial.
  • After 6 days of futile fluconazole therapy he was switched to caspofungin 50 mg q.i.d.
  • Following 63 days of caspofungin without resolution of symptoms, i.e. being persistently febrile, and emergence of soft tissue Candida abscesses, he was included into a trial allowing compassionate use of posaconazole as salvage therapy for refractory invasive fungal infections.
  • Symptoms rapidly resolved under posaconazole 200 mg q.i.d. treatment and the patient was able to undergo allogeneic haematopoietic stem cell transplantation on secondary prophylaxis with posaconazole.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Leukemia, Myeloid, Acute / complications. Salvage Therapy. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Chemoprevention. Drug Resistance, Fungal. Esophagitis / drug therapy. Esophagitis / microbiology. Humans. Male. Mycoses / prevention & control. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961582.001).
  • [ISSN] 0933-7407
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 6TK1G07BHZ / posaconazole
  •  go-up   go-down


36. Nakamura S, Yamashita M, Yokota D, Hirano I, Ono T, Fujie M, Shibata K, Niimi T, Suyama T, Maddali K, Asai K, Yamashita J, Iguchi Y, Ohnishi K: Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity. Invest New Drugs; 2010 Aug;28(4):381-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
  • Both agents showed inhibitory effects on leukemia cell proliferation, with mean IC(50) values of 6.25 micromol/L for TMPP and 23.7 micromol/L for DMPP, indicating that inhibition appeared to be dependent on the number of bromine atoms in the structure.
  • Further, TMPP at 10 micromol/L and DMPP at 20 micromol/L induced G2/M cell cycle block in leukemia cells, and TMPP at 20 micromol/L induced apoptosis in these cells.
  • TMPP treatment effected a reduction in both cell cycle progression signals (FoxM1, KIS, Cdc25B, Cyclin D1, Cyclin A, and Aurora-B) and tumor cell survival (p27(Kip1) and p21(Cip1)), as well as induced the activation of caspase-3 and -9.
  • Further, treatment with TMPP significantly reduced the viability of AML specimens derived from AML patients, but only slightly reduced the viability of normal ALDH(hi) progenitor cells.
  • We also observed that FoxM1 mRNA was overexpressed in AML cells, and treatment with TMPP reduced FoxM1 mRNA expression in AML cells.
  • Here, we report on the synthesis of TMPP and DMPP and demonstrate that these agents hinder proliferation of leukemia cells by FoxM1 suppression, which leads to G2/M cell cycle block and subsequent caspase-3-dependent apoptosis in acute leukemia cells.
  • These agents may facilitate the development of new strategies in targeted antileukemic therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cyclic P-Oxides / pharmacology. Drug Screening Assays, Antitumor / methods. Leukemia / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Organophosphorus Compounds / pharmacology
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Caspase 3 / metabolism. Caspase 9 / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Forkhead Box Protein M1. Forkhead Transcription Factors / metabolism. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Org Lett. 2002 Jan 10;4(1):103-6 [11772101.001]
  • [Cites] FEBS Lett. 2001 Oct 19;507(1):59-66 [11682060.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16881-6 [12482952.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9229-33 [3264071.001]
  • [Cites] Tetrahedron. 1968 Mar;24(5):2125-44 [5636917.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):935-44 [9816064.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12 ):8570-80 [10567581.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1497-501 [9822382.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2199-206 [11877298.001]
  • [Cites] Cell. 1995 Sep 22;82(6):915-25 [7553852.001]
  • [Cites] J Med Chem. 1972 Nov;15(11):1150-4 [4347550.001]
  • [Cites] Leukemia. 2000 Jan;14(1):28-33 [10637473.001]
  • [Cites] Carbohydr Res. 1984 May 15;128(1):61-72 [6234061.001]
  • [Cites] Curr Biol. 1998 Dec 3;8(24):1327-30 [9843684.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1851-7 [17541033.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):453-60 [17984092.001]
  • [Cites] Leukemia. 1993 Feb;7(2):241-5 [8426477.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12 ):5181-9 [15958562.001]
  • [Cites] J Med Chem. 1993 Apr 16;36(8):1048-52 [8478904.001]
  • (PMID = 19436953.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2,3,4-tribromo-3-methyl-1-phenylphospholane 1-oxide; 0 / 2,3-dibromo-3-methyl-1-phenylphospholane 1-oxide; 0 / Antineoplastic Agents; 0 / Cyclic P-Oxides; 0 / FOXM1 protein, human; 0 / Forkhead Box Protein M1; 0 / Forkhead Transcription Factors; 0 / Organophosphorus Compounds; 0 / phospholenes; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


37. Nakai K, Tajima K, Kishimoto Y, Katsura K, Kawamura M, Yamamoto Y, Hanada M, Zen K, Amakawa R, Fujimoto M, Fukuhara S: [Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance]. Rinsho Ketsueki; 2000 Jan;41(1):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In October 1996, a 26-year-old woman was given a diagnosis of acute myeloblastic leukemia, FAB subtype M1.
  • Treatment with combined chemotherapy achieved a complete remission (CR).
  • Successful engraftment was obtained and signs of acute or chronic GVHD never developed.
  • Single-photon-emission computed tomography revealed blood-flow disturbances in the brain, suggesting the recurrence of microthrombosis.
  • We suggest that careful examination of the ocular base may be useful for the early detection of BMT-TM.
  • [MeSH-minor] Adult. Aspirin / therapeutic use. Dipyridamole / therapeutic use. Female. Humans. Leukemia, Myeloid, Acute / therapy. Microcirculation. Plasma. Prednisolone / therapeutic use. Recurrence. Treatment Outcome


38. Nørgaard JM, Olesen LH, Olesen G, Meyer K, Kristensen JS, Bendix K, Pedersen B, Kjeldsen E, Hokland P: FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. Eur J Haematol; 2001 Oct;67(4):221-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
  • In 145 adult patients diagnosed with non-M3 acute myeloid leukaemia (AML) the relevance of FAB-subtype and immunophenotype to in vitro cellular drug resistance towards the anthracyclines aclarubicin (Acla) and daunorubicin (Dau), and the nucleoside analogue cytarabine (Ara-C), as well as other antileukaemic drugs, was investigated using a 4-d MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay.
  • FAB subtypes with highest and lowest cellular Ara-C resistance were M4 and M5, respectively (P < 0.01, one-way anova), whereas FAB subtypes with highest and lowest cellular Dau resistance were M4 and M1, respectively (P < 0.01, one-way anova).
  • By contrast, no significant differences in cellular drug resistance towards Acla could be demonstrated among FAB subtypes.
  • [MeSH-major] Antigens, CD14 / analysis. Antigens, Neoplasm / analysis. Cytarabine / pharmacology. Daunorubicin / pharmacology. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Leukemia, Myelomonocytic, Acute / drug therapy. Neoplastic Stem Cells / chemistry
  • [MeSH-minor] Aclarubicin / administration & dosage. Aclarubicin / pharmacology. Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Amsacrine / administration & dosage. Amsacrine / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Cohort Studies. Doxorubicin / administration & dosage. Doxorubicin / pharmacology. Etoposide / administration & dosage. Etoposide / pharmacology. Female. Humans. Idarubicin / administration & dosage. Idarubicin / pharmacology. Leukemia, Myeloid / classification. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Leukemia, Myeloid / mortality. Leukemia, Myeloid / pathology. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / pharmacology. Multivariate Analysis. Thioguanine / administration & dosage. Thioguanine / pharmacology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860442.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, Neoplasm; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 74KXF8I502 / Aclarubicin; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; FTK8U1GZNX / Thioguanine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


39. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M, Children's Oncology Group phase 1 study: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood; 2004 Nov 1;104(9):2655-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
  • Among 12 chronic myeloid leukemia (CML) patients evaluable for cytogenetic response, 10 had a complete response and 1 had a partial response.
  • Among 10 acute lymphoblastic leukemia (ALL) patients evaluable for morphologic response, 7 achieved an M1 and 1 achieved an M2 bone marrow.
  • [MeSH-major] Leukemia / drug therapy. Leukemia / genetics. Philadelphia Chromosome. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Child. Child, Preschool. Dose-Response Relationship, Drug. Humans. Imatinib Mesylate. Infant. Pharmacokinetics. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15231574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


40. Okamoto Y, Tsuda T, Matsunami M, Hirose T, Sakaguchi R, Katayama N, Ota K: Treatment of acute myeloblastic leukaemia in a patient with Bombay blood type: a case report. J Int Med Res; 2001 Mar-Apr;29(2):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute myeloblastic leukaemia in a patient with Bombay blood type: a case report.
  • A 62-year-old female was admitted to our hospital with suspected acute leukaemia and after investigation we diagnosed acute myeloblastic leukaemia (AML-M1).
  • The patient's blood type was found to be the very rare Bombay type and surveillance of her relatives showed the same blood type in her male cousin on her mother's side.
  • Alongside chemotherapy the patient received 4000 ml of frozen Bombay-type red cells, 1400 ml of concentrated red cells in manitol adenine phosphate solutions and 360 units of type O concentrated platelets without marked effects.
  • The anti-H antibody was initially at 128 dilution but for unknown reasons increased to 2048 dilution after remission of AML-M1.
  • Although AML-M1 is a common adult leukaemia and is chemosensitive to anti-leukaemic drugs, neither AML-M1 in a patient with Bombay-type red cells nor its treatment with chemotherapy and transfusion with type Oh frozen red cells have previously been reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blood Group Antigens. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11393347.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Group Antigens
  •  go-up   go-down


41. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N: Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res; 2004 Apr 15;10(8):2675-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia.
  • The object of this study was to examine whether these polymorphisms may modulate susceptibility to the development of acute myeloid leukemia (AML), a disease that is characterized by genetic instability.
  • EXPERIMENTAL DESIGN: We studied the distribution of polymorphisms in RAD51 and XRCC3 in 216 cases of de novo AML, 51 cases of therapy-related AML (t-AML), and 186 control subjects using PCR followed by restriction enzyme digestion.
  • The polymorphic deletion of the detoxification gene glutathione S-transferase M1 (GSTM1) was also examined by PCR.
  • RESULTS: The risk of the development of AML was found to be significantly increased when both variant RAD51-135C and XRCC3-241Met alleles are present [odds ratio (OR), 3.77; 95% confidence interval (CI), 1.39-10.24], whereas the risk of t-AML development is even higher (OR, 8.11; 95% CI, 2.22-29.68), presumably because of the large genotoxic insult these patients receive after their exposure to radiotherapy or chemotherapy.
  • [MeSH-major] DNA Repair. Leukemia, Myeloid, Acute / genetics. Polymorphism, Genetic. Recombination, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alleles. DNA Damage. Genetic Predisposition to Disease. Genotype. Glutathione Transferase / genetics. Humans. Logistic Models. Middle Aged. Odds Ratio. Phenotype. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Risk

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15102670.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down






Advertisement